Bar-Ilan University wins dual ERC grants for groundbreaking research in life sciences and AI policy analysis
Grant and Award Announcement
Updates every hour. Last Updated: 12-Sep-2025 16:11 ET (12-Sep-2025 20:11 GMT/UTC)
Two cutting-edge research projects at Bar-Ilan University have been awarded Proof of Concept (PoC) Grants from the European Research Council (ERC)—a major achievement that highlights the university’s interdisciplinary leadership in both biomedical science and AI-driven public policy.
MUSC Hollings Cancer Center researchers have discovered a hidden feedback loop that helps leukemia cells survive and have developed a new immunotherapy that can break that loop. The loop is between a protein called IL-33 and its receptor IL1RL1, which together help acute myeloid leukemia cells grow and evade treatment. To disrupt this loop, the researchers created a bispecific antibody that both kills leukemia cells carrying IL1RL1 and activates immune cells that can fight off cancer. In lab and animal models, the therapy significantly slowed disease progression, reduced immune suppression and improved survival without major side effects. The research offers a potential new off-the-shelf treatment for leukemia and other cancers with similar tumor environments.
Singapore researchers have discovered that a Singapore-developed cancer drug, originally developed at A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB), shows potential as a new treatment approach for two leading causes of blindness worldwide. In pre-clinical studies published in Nature Communications, PRL3-zumab effectively reduced leakage from damaged blood vessels—a major cause of vision loss—showing promise as a potential new treatment for patients whose conditions do not respond well to current therapies.
In a paper published in Mycology, an international team of scientists mainly reported the isolation and characterization of two new pairs of (±)-penithrones A (1) and B (2), and a chlorinated derivative (±)-penithrone C (3), along with their biogenetic precursors (4–6), from the mangrove-derived fungus Penicillium hispanicum LA032. The study demonstrated significant cytotoxic activity of compounds 1 and 2 against multiple cancer cell lines (IC50 = 5.09–9.47 μmol/L), and identified MAPK10 as a potential molecular target through integrated network pharmacology and molecular docking approaches, providing new insights into fungal-derived anticancer agents.
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/15/issue/7
Acta Pharmaceutica Sinica B (APSB) was founded with the goal of creating a global high-level forum centred around drug discovery and pharmaceutical research/application. APSB was included by Chemical Abstracts in 2011, accepted by PubMed Central in 2015, indexed by Science Citation Index in 2017 and has evolved to become one of the most important international journals in the field of pharmaceutical sciences.
A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they experienced positive outcomes that support use of targeted radiation in the future for such patients. Results are published in the Journal of Clinical Oncology.
In biology textbooks and beyond, the human genome and DNA therein typically are taught in only one dimension. While it can be helpful for learners to begin with the linear presentation of how stretches of DNA form genes, this oversimplification undersells the significance of the genome’s 3D structure. Problems with this 3D structure are associated with many diseases including developmental disorders and cancer.
Scientists at Sanford Burnham Prebys and colleagues in Hong Kong published findings June 27, 2025, in Genome Biology demonstrating a new approach for better understanding the human genome’s 3D structure and its influence.